Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm

DelveInsight's, "Nephrotic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nephrotic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's analysis indicates that over three key companies are actively engaged in developing more than three therapies for Nephrotic Syndrome.

Nephrotic Syndrome Overview:

Nephrotic Syndrome is a group of symptoms indicating impaired kidney function. Common signs include high protein levels in the urine, low protein levels in the blood, elevated blood fats or cholesterol, and swelling in different parts of the body. While it can affect anyone, it is slightly more common in men, and in children, it typically appears between ages 2 and 6.

In adults, the most frequent primary cause of nephrotic syndrome is focal segmental glomerulosclerosis (FSGS), a kidney disease that can only be definitively diagnosed through a kidney biopsy. Even with treatment, many people with FSGS may progress to kidney failure, requiring dialysis or a kidney transplant. There is also a risk that FSGS can recur after a transplant, potentially affecting the new kidney.

Download our report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Nephrotic Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nephrotic Syndrome Therapeutics Market.

Key Takeaways from the Nephrotic Syndrome Pipeline Report

*
DelveInsight's Nephrotic Syndrome pipeline report highlights a dynamic landscape with more than three active companies working to develop over three therapies for the condition.

*
In March 2025, the FDA approved scPharmaceuticals' supplemental New Drug Application (sNDA) to expand FUROSCIX (furosemide injection) for treating edema in adult patients with chronic kidney disease, including those with nephrotic syndrome. FUROSCIX, a subcutaneous furosemide injection, was previously approved for chronic heart failure and now addresses fluid overload, a serious complication in CKD patients.

*
Also in March 2025, ANI Pharmaceuticals received FDA approval for a new prefilled syringe version of Purified Cortrophin Gel (repository corticotropin injection), indicated for multiple conditions including inducing diuresis or remission of proteinuria in nephrotic syndrome, whether idiopathic or lupus-related, without uremia.

*
Key companies advancing treatments for nephrotic syndrome include GlaxoSmithKline, Goldfinch Bio, Travere Therapeutics, Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others. Promising pipeline therapies in development include Belimumab and additional candidates.

Nephrotic Syndrome Pipeline Analysis

The Nephrotic Syndrome pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Nephrotic Syndrome Market.

*
Categorizes Nephrotic Syndrome therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Nephrotic Syndrome drugs under development based on:

*
Stage of development

*
Nephrotic Syndrome Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Nephrotic Syndrome Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Nephrotic Syndrome Licensing agreements

*
Funding and investment activities supporting future Nephrotic Syndrome market advancement.

Request for a sample report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Nephrotic Syndrome Emerging Drugs

*
Belimumab: GlaxoSmithKline

Nephrotic Syndrome Companies

Approximately three or more leading companies are actively developing therapies for Nephrotic Syndrome. Among these, GlaxoSmithKline has a drug candidate that has advanced to the most progressed stage of development-Phase II clinical trials.

DelveInsight's report covers around 3+ products under different phases of Nephrotic Syndrome clinical trials like

*
Nephrotic Syndrome Late stage Therapies (Phase III)

*
Nephrotic Syndrome Mid-stage Therapies (Phase II)

*
Nephrotic Syndrome Early-stage Therapies (Phase I)

*
Nephrotic Syndrome Pre-clinical and Nephrotic Syndrome Discovery stage Therapies

*
Nephrotic Syndrome Discontinued & Inactive Therapies

Nephrotic Syndrome pipeline report provides the Nephrotic Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Nephrotic Syndrome Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Nephrotic Syndrome Therapies and Key Nephrotic Syndrome Companies: Nephrotic Syndrome Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Nephrotic Syndrome Pipeline Therapeutic Assessment

- Nephrotic Syndrome Assessment by Product Type

- Nephrotic Syndrome By Stage

- Nephrotic Syndrome Assessment by Route of Administration

- Nephrotic Syndrome Assessment by Molecule Type

Download Nephrotic Syndrome Sample report to know in detail about the Nephrotic Syndrome treatment market @ Nephrotic Syndrome Therapeutic Assessment [https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Nephrotic Syndrome Current Treatment Patterns

4. Nephrotic Syndrome - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Nephrotic Syndrome Late-Stage Products (Phase-III)

7. Nephrotic Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nephrotic Syndrome Discontinued Products

13. Nephrotic Syndrome Product Profiles

14. Nephrotic Syndrome Key Companies

15. Nephrotic Syndrome Key Products

16. Dormant and Discontinued Products

17. Nephrotic Syndrome Unmet Needs

18. Nephrotic Syndrome Future Perspectives

19. Nephrotic Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Nephrotic Syndrome Pipeline Reports Offerings [https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nephrotic-syndrome-pipeline-analysis-2025-by-delveinsight-glaxosmithkline-goldfinch-bio-inc-travere-therapeutics-inc-aurinia-pharmaceuticals-bristolmyers-squibb-chemocentryx-synact-pharm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.